KDP2

KDP2 is an experimental **mitochondria-targeted biotin-conjugated BODIPY photosensitizer** reported in preclinical research for **photodynamic therapy** and cancer imaging. It was described alongside KDP1 as a synthetic BODIPY-biotin conjugate with strong light absorption, measurable singlet oxygen generation, mitochondrial localization, and potent photocytotoxicity in MDA-MB-231 breast cancer cells. Its apparent antitumor mechanism is light-activated reactive oxygen species generation leading to mitochondrial damage and predominantly apoptotic cell death. No evidence from the provided source establishes commercial development, branded use, or clinical-stage development by a specific company.